Document Type : Review Article


1 Department of Urology, JN Medical College, KLE Academy of Higher Education & Research, JNMC Campus, Belagavi-590010, Karnataka, India

2 Urinary Biomarkers Research Centre, Department of Urology, KLES Kidney Foundation, KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi-590010, Karnataka, India


The COVID-19 pandemic will have numerous consequences in the management of patients
with genitourinary cancers. As we are struggling to best exploit our limited health-care
resources in managing COVID-19 infected patients, we need to rethink our approach to
provide the best medical care for cancer patients in the time of this global crisis. There
is a need for a decision-making algorithm which takes into account the age, presenting
symptoms, comorbid illnesses, access to health-care services, and availability of qualified
health-care personnel. We must provide support, a clear and comprehensible information
along with essential care to the patients seeking medical opinion during a time of this
unforeseen global health crisis. In this mini review we have made an attempt to prioritize
the necessity of intervention in urological oncology patients as per various national and
international guidelines. This approach should be tailored as per locally available healthcare resources and the burden of COVID-19 infected cases in that region.


Main Subjects

  1. Nouhaud FX, Bernhard JC, Bigot P, Khene ZE, Audenet F, Lang H, et al. Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). World J Urol 2018; 36(10): 1643-9. doi:10.1007/s00345-018-2307-6.
    2. Mehrazin R, Smaldone MC, Kutikov A, Li T, Tomaszewski JJ, Canter DJ, et al. Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. J Urol 2014; 192(3): 659-64. doi: 10.1016/j.juro.2014.03.038.
    3. McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, et al. Active surveillance for localized
    renal masses: tumor growth, delayed intervention rates, and > 5-yr clinical outcomes. Eur Urol 2018; 74(2): 157-64.doi: 10.1016/j.eururo.2018.03.011.
    4. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM
    registry. Eur Urol 2015; 68(3): 408-15. doi: 10.1016/j.eururo.2015.02.001.
    5. Nerli RB. Cytoreductive nephrectomy for metastatic renal cell carcinoma. J Sci Soc. 2013; 40(2): 64-7. doi: 10.4103/kleuhsj.kleuhsj_116_20.
    6. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in
    metastatic renal-cell carcinoma. N Engl J Med 2018; 379(5): 417-27. doi: 10.1056/NEJMoa1803675.
    7. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred
    cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the
    SURTIME randomized clinical trial. JAMA Oncol 2019; 5(2): 164-70. doi: 10.1001/jamaoncol.2018.5543.
    8. Barghi MR, Rahmani MR, Hosseini Moghaddam SM, Jahanbin M. Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell
    carcinoma of bladder. Urol J 2006; 3(4): 220-4.
    9. Jones JS. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier;2016. p. 2214-15.
    10. Little P. Non-steroidal anti-inflammatory drugs and COVID-19. BMJ 2020; 368: m1185. doi: 10.1136/bmj.m1185.
    11. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, et al. Delaying radical cystectomy after
    neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes.
    Eur Urol Oncol 2019; 2(4): 390-6. doi: 10.1016/j.euo.2018.09.004.
    12. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, et al. A delay in radical nephroureterectomy
    can lead to upstaging. BJU Int 2010; 105(6): 812-7. doi:10.1111/j.1464-410X.2009.08821.x.
    13. Pryor A. SAGES Recommendations Regarding Surgical Response to COVID-19 Crisis - SAGES [Internet]. Society of American Gastrointestinal and Endoscopic Surgeons.2020 [cited 24 Apr 2020]. Available from:
    14. Updated Intercollegiate General Surgery Guidance on COVID-19 [Internet]. Royal College of Surgeons. 2020
    [cited 24 Apr 2020]. Available from:
    15. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg 2020; 107(7): 785-7. doi:10.1002/bjs.11627.
    16. Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell’Oglio P, Moschini M, et al. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: can surgery be postponed safely? Urol Oncol 2017;35(4): 150.e9-150.e15. doi: 10.1016/j.urolonc.2016.11.010.
    17. Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, et al. Immediate versus delayed prostatectomy: nationwide population-based study. Scand J Urol 2016; 50(4): 246-54. doi:10.3109/21681805.2016.1166153.
    18. Shabbir M, Kayes O, Minhas S. Challenges and controversies in the management of penile cancer. Nat Rev Urol 2014;11(12): 702-11. doi: 10.1038/nrurol.2014.307.
    19. Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, et al. Delay to inguinal lymph node dissection greater than 3 months predicts poorer recurrence-free survival for patients with penile cancer. J Urol 2017; 198(6):1346-52. doi: 10.1016/j.juro.2017.06.076.
    20. Ficarra V, Akduman B, Bouchot O, Palou J, Tobias-Machado M. Prognostic factors in penile cancer. Urology 2010; 76(2Suppl 1): S66-73. doi: 10.1016/j.urology.2010.04.008.
    21. Leone A, Diorio GJ, Pettaway C, Master V, Spiess PE. Contemporary management of patients with penile cancer and lymph node metastasis. Nat Rev Urol 2017; 14(6): 335-47. doi: 10.1038/nrurol.2017.47.
    22. Bourgade V, Drouin SJ, Yates DR, Parra J, Bitker MO, Cussenot O, et al. Impact of the length of time between
    diagnosis and surgical removal of urologic neoplasms on survival. World J Urol 2014; 32(2): 475-9. doi: 10.1007/